CL2019003496A1 - Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. - Google Patents
Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.Info
- Publication number
- CL2019003496A1 CL2019003496A1 CL2019003496A CL2019003496A CL2019003496A1 CL 2019003496 A1 CL2019003496 A1 CL 2019003496A1 CL 2019003496 A CL2019003496 A CL 2019003496A CL 2019003496 A CL2019003496 A CL 2019003496A CL 2019003496 A1 CL2019003496 A1 CL 2019003496A1
- Authority
- CL
- Chile
- Prior art keywords
- patients
- treatment methods
- kidney failure
- fabry disease
- patient
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000024720 Fabry Disease Diseases 0.000 title abstract 2
- 208000001647 Renal Insufficiency Diseases 0.000 title abstract 2
- 201000006370 kidney failure Diseases 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 230000002861 ventricular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
Abstract
SE PROPORCIONAN MÉTODOS PARA EL TRATAMIENTO DE LA ENFERMEDAD DE FABRY EN UN PACIENTE QUE TIENE INSUFICIENCIA RENAL Y/O PROTEINURIA ELEVADA. DETERMINADOS MÉTODOS COMPRENDEN ADMINISTRAR AL PACIENTE DE APROXIMADAMENTE 100 A APROXIMADAMENTE 150 MG DE EQUIVALENTE DE BASE LIBRE DE MIGALASTAT O SAL DEL MISMO A UNA FRECUENCIA DE UNA VEZ CADA DOS DÍAS. DETERMINADOS MÉTODOS TAMBIÉN PROPORCIONAN LA ESTABILIZACIÓN DE LA FUNCIÓN RENAL, LA REDUCCIÓN DEL ÍNDICE DE MASA VENTRICULAR IZQUIERDA, LA REDUCCIÓN DE LA GLOBOTRIAOSILESFINGOSINA Y/O EL AUMENTO DE LA ACTIVIDAD DE Α-GALACTOSIDASA A EN EL PACIENTE.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762512458P | 2017-05-30 | 2017-05-30 | |
| US201862626953P | 2018-02-06 | 2018-02-06 | |
| US15/992,336 US10251873B2 (en) | 2017-05-30 | 2018-05-30 | Methods of treating fabry patients having renal impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003496A1 true CL2019003496A1 (es) | 2020-06-05 |
Family
ID=62705693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003496A CL2019003496A1 (es) | 2017-05-30 | 2019-11-29 | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. |
| CL2024000915A CL2024000915A1 (es) | 2017-05-30 | 2024-03-27 | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000915A CL2024000915A1 (es) | 2017-05-30 | 2024-03-27 | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal |
Country Status (11)
| Country | Link |
|---|---|
| US (45) | US10251873B2 (es) |
| JP (7) | JP2020507562A (es) |
| KR (6) | KR20240017112A (es) |
| AU (2) | AU2018277756A1 (es) |
| BR (1) | BR112019025083B1 (es) |
| CA (4) | CA3224529A1 (es) |
| CL (2) | CL2019003496A1 (es) |
| CO (1) | CO2019015026A2 (es) |
| IL (1) | IL270956A (es) |
| MX (2) | MX391565B (es) |
| WO (1) | WO2018222655A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE027569T2 (en) | 2006-05-16 | 2016-10-28 | Amicus Therapeutics Inc | Preparation for the treatment of Fabry disease |
| CA2715407C (en) | 2008-02-12 | 2022-07-26 | Elfrida Benjamin | Method to predict response to pharmacological chaperone treatment of diseases |
| WO2017165164A1 (en) * | 2016-03-22 | 2017-09-28 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having the g9331a mutation in the gla gene |
| AU2018277756A1 (en) * | 2017-05-30 | 2020-01-23 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| EP3749307A1 (en) | 2018-02-06 | 2020-12-16 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| MX2021002070A (es) * | 2018-08-20 | 2021-07-15 | Amicus Therapeutics Inc | Metodos para tratar la enfemedad de fabry en pacientes que tienen una mutacion en el gen gla. |
| MX2021015352A (es) * | 2019-06-11 | 2022-04-06 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
| AU2020327019A1 (en) | 2019-08-07 | 2022-03-03 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| US11623916B2 (en) | 2020-12-16 | 2023-04-11 | Amicus Therapeutics, Inc. | Highly purified batches of pharmaceutical grade migalastat and methods of producing the same |
| USD961304S1 (en) * | 2021-05-25 | 2022-08-23 | Paolo Castelli | Furniture for bathrooms |
| USD960619S1 (en) * | 2021-05-26 | 2022-08-16 | Paolo Castelli | Furniture for bathrooms |
| WO2023204173A1 (ja) | 2022-04-22 | 2023-10-26 | 京セラ株式会社 | 制御端末、基地局、及び通信方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| US7973157B2 (en) | 2005-06-08 | 2011-07-05 | Amicus Therapeutics, Inc. | Imino and amino sugar purification |
| HUE027569T2 (en) | 2006-05-16 | 2016-10-28 | Amicus Therapeutics Inc | Preparation for the treatment of Fabry disease |
| AU2008232614A1 (en) | 2007-03-30 | 2008-10-09 | Amicus Therapeutics, Inc. | Method for the treatment of Fabry disease using pharmacological chaperones |
| WO2008134628A2 (en) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| US9999618B2 (en) | 2007-04-26 | 2018-06-19 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| CA2715407C (en) | 2008-02-12 | 2022-07-26 | Elfrida Benjamin | Method to predict response to pharmacological chaperone treatment of diseases |
| US8321148B2 (en) | 2008-10-24 | 2012-11-27 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
| US9206457B2 (en) | 2009-05-26 | 2015-12-08 | Amicus Therapeutics, Inc. | Utilization of pharmacological chaperones to improve manufacturing and purification of biologics |
| US20110070643A1 (en) | 2009-05-26 | 2011-03-24 | Do Hung V | Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics |
| WO2011007453A1 (ja) * | 2009-07-17 | 2011-01-20 | Ｎｅｃディスプレイソリューションズ株式会社 | 絞り制御回路、プロジェクター装置、絞り制御プログラム及び絞り制御方法 |
| ES2568610T3 (es) | 2009-11-17 | 2016-05-03 | Baylor Research Institute | Triaosilceramida (Gb3) urinaria como un marcador de cardiopatías |
| CA2829947C (en) * | 2011-03-11 | 2019-01-15 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of fabry disease |
| US20120283290A1 (en) * | 2011-05-06 | 2012-11-08 | Amicus Therapeutics Inc. | Quantitation of gl3 in urine |
| US20150258081A1 (en) | 2011-12-22 | 2015-09-17 | Centogene Ip Gmbh | Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
| US9694056B2 (en) | 2012-07-17 | 2017-07-04 | Amicus Therapeutics, Inc. | α-galactosidase A and 1-deoxygalactonojirimycin co-formulation |
| US10155027B2 (en) | 2012-07-17 | 2018-12-18 | Amicus Therapeutics, Inc. | Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease |
| US20170051267A1 (en) | 2015-08-20 | 2017-02-23 | Research Foundation Of The City University Of New York | Novel alpha-galactosidase a derivatives |
| WO2017165164A1 (en) | 2016-03-22 | 2017-09-28 | Amicus Therapeutics, Inc. | Methods of treating fabry disease in patients having the g9331a mutation in the gla gene |
| TWI875676B (zh) | 2016-07-19 | 2025-03-11 | 美商阿米庫斯醫療股份有限公司 | 治療ert初治的和已經歷ert的患者中之法布瑞氏症 |
| TW201829770A (zh) | 2017-01-10 | 2018-08-16 | 美商阿米庫斯醫療股份有限公司 | 用於治療fabry氏病之重組α-半乳糖苷酶A |
| AU2018277756A1 (en) * | 2017-05-30 | 2020-01-23 | Amicus Therapeutics, Inc. | Methods of treating fabry patients having renal impairment |
| CN107126301B (zh) | 2017-06-14 | 2018-05-22 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 一种用于侧方入路治疗腰椎滑移的椎间融合器 |
| SG11202000423XA (en) | 2017-07-19 | 2020-02-27 | Amicus Therapeutics Inc | Treatment of fabry disease in ert-naïve and ert-experienced patients |
| AU2018326364B2 (en) | 2017-08-28 | 2024-08-29 | Amicus Therapeutics, Inc. | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease |
| EP3749307A1 (en) | 2018-02-06 | 2020-12-16 | Amicus Therapeutics, Inc. | Use of migalastat for treating fabry disease in pregnant patients |
| CA3090499A1 (en) | 2018-02-06 | 2019-08-15 | Amicus Therapeutics, Inc. | Use of migalastat for the treatment of patients with classic fabry disease |
| MX2021002070A (es) | 2018-08-20 | 2021-07-15 | Amicus Therapeutics Inc | Metodos para tratar la enfemedad de fabry en pacientes que tienen una mutacion en el gen gla. |
| MX2021015352A (es) | 2019-06-11 | 2022-04-06 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal. |
| AU2020327019A1 (en) | 2019-08-07 | 2022-03-03 | Amicus Therapeutics, Inc. | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
| EP4103178A4 (en) | 2020-02-10 | 2024-03-20 | Amicus Therapeutics, Inc. | Methods of treating fabry disease |
-
2018
- 2018-05-30 AU AU2018277756A patent/AU2018277756A1/en not_active Abandoned
- 2018-05-30 KR KR1020247003115A patent/KR20240017112A/ko active Pending
- 2018-05-30 CA CA3224529A patent/CA3224529A1/en active Pending
- 2018-05-30 KR KR1020227025898A patent/KR20220116305A/ko active Pending
- 2018-05-30 CA CA3224537A patent/CA3224537C/en active Active
- 2018-05-30 KR KR1020197038266A patent/KR102631805B1/ko active Active
- 2018-05-30 CA CA3065298A patent/CA3065298C/en active Active
- 2018-05-30 JP JP2019539797A patent/JP2020507562A/ja active Pending
- 2018-05-30 KR KR1020217016473A patent/KR102427610B1/ko active Active
- 2018-05-30 CA CA3224546A patent/CA3224546A1/en active Pending
- 2018-05-30 KR KR1020247003113A patent/KR20240017110A/ko active Pending
- 2018-05-30 BR BR112019025083-2A patent/BR112019025083B1/pt active IP Right Grant
- 2018-05-30 KR KR1020247003114A patent/KR20240017111A/ko active Pending
- 2018-05-30 MX MX2019014410A patent/MX391565B/es unknown
- 2018-05-30 US US15/992,336 patent/US10251873B2/en active Active
- 2018-05-30 WO PCT/US2018/035032 patent/WO2018222655A1/en not_active Ceased
-
2019
- 2019-02-25 US US16/284,582 patent/US10471053B2/en active Active
- 2019-11-08 US US16/678,183 patent/US10874655B2/en active Active
- 2019-11-26 IL IL270956A patent/IL270956A/en unknown
- 2019-11-29 MX MX2022004137A patent/MX2022004137A/es unknown
- 2019-11-29 CL CL2019003496A patent/CL2019003496A1/es unknown
- 2019-12-19 JP JP2019229050A patent/JP6788725B2/ja active Active
- 2019-12-30 CO CONC2019/0015026A patent/CO2019015026A2/es unknown
-
2020
- 2020-03-13 US US16/817,895 patent/US10874657B2/en active Active
- 2020-03-13 US US16/817,908 patent/US10799491B2/en active Active
- 2020-03-13 US US16/817,911 patent/US10792278B2/en active Active
- 2020-03-13 US US16/817,927 patent/US10792279B2/en active Active
- 2020-03-13 US US16/817,877 patent/US10849889B2/en active Active
- 2020-03-13 US US16/817,881 patent/US10857141B2/en active Active
- 2020-03-13 US US16/817,925 patent/US10849890B2/en active Active
- 2020-03-13 US US16/817,918 patent/US10806727B2/en active Active
- 2020-03-13 US US16/817,900 patent/US10857142B2/en active Active
- 2020-03-13 US US16/817,888 patent/US10874656B2/en active Active
- 2020-07-20 JP JP2020123392A patent/JP2020203886A/ja active Pending
- 2020-10-21 US US17/076,340 patent/US11612593B2/en active Active
- 2020-10-21 US US17/076,336 patent/US11633387B2/en active Active
- 2020-10-22 US US17/077,402 patent/US11622962B2/en active Active
- 2020-10-22 US US17/077,393 patent/US11826360B2/en active Active
- 2020-10-22 US US17/077,397 patent/US11642334B2/en active Active
- 2020-10-22 US US17/077,389 patent/US11612594B2/en active Active
- 2020-10-23 US US17/078,840 patent/US12109205B2/en active Active
- 2020-10-23 US US17/078,765 patent/US11633388B2/en active Active
-
2021
- 2021-03-26 US US17/213,632 patent/US11903938B2/en active Active
- 2021-08-04 US US17/393,971 patent/US11304940B2/en active Active
- 2021-08-12 US US17/400,548 patent/US11357761B2/en active Active
- 2021-08-12 US US17/400,922 patent/US11278538B2/en active Active
- 2021-08-12 US US17/400,614 patent/US11357762B2/en active Active
- 2021-08-12 US US17/400,623 patent/US11278536B2/en active Active
- 2021-08-12 US US17/400,626 patent/US11278537B2/en active Active
- 2021-08-12 US US17/400,927 patent/US11278539B2/en active Active
- 2021-08-12 US US17/400,932 patent/US11357763B2/en active Active
- 2021-08-13 US US17/401,629 patent/US11278540B2/en active Active
-
2022
- 2022-02-11 US US17/670,076 patent/US11426396B2/en active Active
- 2022-02-11 US US17/670,088 patent/US11357765B1/en active Active
- 2022-02-11 US US17/670,083 patent/US11357764B1/en active Active
- 2022-02-11 US US17/670,095 patent/US11376244B2/en active Active
- 2022-02-18 US US17/675,536 patent/US11666564B2/en active Active
- 2022-02-18 US US17/675,544 patent/US11458128B2/en active Active
- 2022-02-18 US US17/675,587 patent/US11389437B2/en active Active
- 2022-02-18 US US17/675,532 patent/US11389436B2/en active Active
- 2022-03-02 JP JP2022031518A patent/JP2022071094A/ja not_active Withdrawn
- 2022-12-21 US US18/069,720 patent/US11786516B2/en active Active
- 2022-12-21 JP JP2022204185A patent/JP2023052005A/ja active Pending
- 2022-12-21 US US18/069,716 patent/US11813255B2/en active Active
- 2022-12-21 US US18/069,732 patent/US12280042B2/en active Active
-
2023
- 2023-04-13 JP JP2023065461A patent/JP2023100658A/ja active Pending
- 2023-05-31 US US18/326,279 patent/US12042489B2/en active Active
- 2023-05-31 US US18/326,281 patent/US12042490B2/en active Active
- 2023-05-31 US US18/326,274 patent/US12042488B2/en active Active
-
2024
- 2024-03-27 CL CL2024000915A patent/CL2024000915A1/es unknown
- 2024-07-12 AU AU2024204823A patent/AU2024204823A1/en active Pending
-
2025
- 2025-06-03 JP JP2025092379A patent/JP2025143262A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| AR120055A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| CL2020000491A1 (es) | Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry. | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| CL2018002734A1 (es) | Métodos de tratamiento con vitamina d | |
| CL2022000786A1 (es) | Metodos de tratamiento para modificar la hemodinamica | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| EP4245366A3 (en) | Migalastat for treating fabry patients having renal impairment | |
| AR111971A1 (es) | Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal | |
| EA201992869A1 (ru) | Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность | |
| MX2022006045A (es) | Metodos de administracion de voxelotor. | |
| AR109102A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| Ozcete | Propafenone overdose | |
| UA109966C2 (uk) | Спосіб лікування латентної ішемічної хвороби серця у хворих на бронхіальну астму | |
| EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом |